drugset / Trial / NCT04040361
Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)
Phase 2
Unknown
24 enrolled
Masahiro Tsuboi
Eli Lilly and Company · collabMerck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
The efficacy and safety of the neoadjuvant therapy of pembrolizumab+ ramucirumab
Timeline
- Start
- 2019-11-30
- Primary completion
- 2022-04-30
- Completion
- 2025-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Ramucirumab | Monoclonal antibody | 10 mg/kg | Intravenous |